Amifampridine
RUZURGI
- Dosage form
- Tablet
- Available strengths
- 10 mg
- Drug class
- Potassium channel blocker (aminopyridine)
- Common brand
- RUZURGI
Clinical overview. Amifampridine is a potassium channel blocker (brand name RUZURGI) used to treat the muscle weakness of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years of age and older. It works by improving nerve signal transmission to muscles and is started at a low dose that is gradually titrated based on response and tolerability. Amifampridine carries risks of seizures and heart rhythm changes (QTc prolongation), and it should never be combined with other forms of amifampridine or other aminopyridine drugs.
Indication
Common therapeutic uses
- Amifampridine (RUZURGI) is used for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years of age and older.
- LEMS should be diagnosed by a health professional experienced with this rare autoimmune neuromuscular disease.
- Amifampridine should only be prescribed by health professionals experienced in treating LEMS who can discuss the benefits and risks of treatment with patients.
Pregnancy
Risk assessment and monitoring considerations
- Amifampridine and its metabolite cross the placenta and enter the fetal circulation and amniotic fluid.
- There are no adequate, well-controlled studies of amifampridine in pregnant women.
- Women of childbearing potential should use effective contraception during treatment.
- Amifampridine should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.
Breastfeeding
Infant exposure considerations
- It is not known whether amifampridine or its metabolite pass into human breast milk, or what effect they have on a nursing infant.
- A decision should be made to either discontinue breastfeeding or discontinue the drug, weighing the mother's clinical need for treatment against potential risks to the infant.
Geriatrics
Dosing and tolerability considerations
- No significant difference in safety or effectiveness has been observed between elderly and younger adult patients.
- Older adults more often have reduced liver, kidney, or heart function, so treatment should start at the low end of the dosing range with slower titration.
- Because amifampridine is substantially cleared by the kidneys, monitoring renal function may be useful in older patients.
Pediatrics
Use in children and adolescents
- Safety and efficacy in children younger than 6 years of age have not been studied, and amifampridine is not indicated for this age group.
- Use in patients 6 to 17 years of age is supported by evidence from adult LEMS studies, adult pharmacokinetic data, and pharmacokinetic modeling used to identify the pediatric dosing regimen.
- Adverse reactions reported in pediatric patients treated in Expanded Access Programs were similar to those seen in adults.
Dosage & Administration
Practical dosing and administration
- In patients weighing less than 45 kg, the initial dose is 5 mg to 10 mg daily in divided doses (2 to 3 times per day), titrated upward in 2.5 mg to 5 mg increments to a maximum single dose of 10 mg and a maximum total daily dose of 40 mg.
- In patients weighing 45 kg or more, the initial dose is 10 mg to 20 mg daily in divided doses (2 to 3 times per day), titrated upward in 5 mg to 10 mg increments to a maximum single dose of 20 mg and a maximum total daily dose of 80 mg, though some patients may benefit from up to 100 mg daily.
- Patients who are known slow acetylators of the NAT2 enzyme should be started at the lowest recommended dose for their weight, since they clear the drug more slowly and have higher exposure.
- In mild to moderate hepatic impairment, treatment should start at the lowest recommended dose, with a maximum of 20 mg daily for patients under 45 kg and 40 mg daily for patients 45 kg or more; dosing has not been established for severe hepatic impairment.
- In mild, moderate, or severe renal impairment, treatment should be titrated more slowly starting at the lowest dose, with a maximum of 20 mg daily for patients under 45 kg and 40 mg daily for patients 45 kg or more; dosing has not been established for end-stage renal disease or dialysis.
- A 1 mg/mL oral suspension can be prepared for patients who need smaller dose increments, have difficulty swallowing, or use a feeding tube, and is stable under refrigeration for up to 24 hours.
- If a dose is missed by a few hours and weakness is noticed, the usual dose should be taken as soon as possible; if it is close to the next scheduled dose, the missed dose should be skipped rather than doubled.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Overdose from repeated doses in patients already on stable amifampridine therapy has caused diffuse muscle spasms and chest, abdominal, or back pain.
- At higher doses (300 mg per day or more), overdose has caused vomiting, seizures, status epilepticus, and rhabdomyolysis (muscle tissue breakdown).
- Cardiac effects reported at these higher doses include chest pain, palpitations, paroxysmal supraventricular tachycardia, transient QTc prolongation, and cardiac arrest.
- Aspiration with acute respiratory failure has also been reported at overdose doses.
- Patients with suspected overdose should be monitored for exaggerated drug effects, receive prompt symptomatic treatment, and undergo ECG monitoring.
Common side effects
Frequently reported tolerability concerns
- A tingling, burning, or prickling sensation in or around the mouth (oral dysaesthesia) is very common.
- Abdominal pain is very common.
- Indigestion (dyspepsia) is common.
- Nausea is common.
- Diarrhea may occur.
- Tingling or altered sensation elsewhere in the body (dysaesthesia) is very common.
- Dizziness is common.
- Back pain may occur.
- Muscle spasms may occur.
- Numbness (hypoesthesia) may occur.
- Altered sense of taste may occur.
- Pain in an arm or leg may occur.
- Hiccups may occur.
- Hot flushes may occur.
- Chest discomfort may occur.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Amifampridine can cause seizures, even in patients with no prior history, and the risk may increase with higher doses.
- Amifampridine can prolong the QTc interval, particularly in NAT2 slow acetylators, raising the risk of a dangerous heart rhythm disturbance called torsade de pointes.
- Severe allergic reactions, including anaphylaxis, have been associated with other aminopyridines and could occur with amifampridine.
- Falls have been reported frequently in long-term follow-up of patients with LEMS treated with amifampridine.
- Pneumonia and worsening shortness of breath have been reported in long-term follow-up.
- Suddenly stopping amifampridine can cause a return or worsening of LEMS symptoms, including difficulty moving, getting out of bed, swallowing, or breathing; these symptoms generally resolve after resuming the prior dose.
- Seek urgent medical attention for a seizure, a fast or irregular heartbeat, fainting, or signs of a severe allergic reaction such as swelling of the face or throat or difficulty breathing.
Use with caution
Situations requiring closer assessment
- Use with caution in patients who are known NAT2 slow acetylators, starting at the lowest recommended dose.
- Use with caution in patients with any degree of hepatic impairment, since amifampridine is extensively metabolized by the liver.
- Use with caution in patients with renal impairment, since amifampridine and its metabolite are cleared by the kidneys and can accumulate.
- Correct low potassium, calcium, or magnesium levels before starting or continuing amifampridine, and use caution in patients with other risk factors for torsade de pointes, including female sex, age 65 or older, a slow heart rate, or a history of arrhythmia.
- Use with caution in patients with a history of seizures or tremor, or in combination with other drugs known to lower the seizure threshold.
- Use with caution in older adults, starting at the low end of the dosing range.
- Do not use amifampridine together with other forms of amifampridine or other aminopyridines, due to the risk of overdose.
Contraindications
Situations where therapy may be inappropriate
- Contraindicated in patients with known hypersensitivity to amifampridine or to any ingredient in the formulation.
- Contraindicated in patients with a history of seizures.
- Contraindicated in combination with other forms of amifampridine or other aminopyridines.
Drug interactions
Clinically relevant combinations
- Drugs with cholinergic effects, such as pyridostigmine, may have additive cholinergic effects when combined with amifampridine.
- Drugs that lower the seizure threshold may increase the risk of seizures when combined with amifampridine.
- Drugs known to prolong the QT interval may add to amifampridine's effect on QTc prolongation.
- Drugs that reduce blood potassium, calcium, or magnesium levels, including loop and thiazide diuretics, laxatives and enemas, amphotericin B, and high-dose corticosteroids, may increase the risk of QTc prolongation when combined with amifampridine.
Food interactions
Meal-related administration
- Amifampridine can be taken with or without food, so either approach is acceptable.
- Taking amifampridine with food may help reduce mouth tingling and abdominal discomfort.
Time of administration
Practical scheduling
- Amifampridine is taken in divided doses, 2 to 3 times daily (up to 5 times daily during titration), and can be taken with or without food.
Storage
Product handling
- Before dispensing, store tablets under refrigeration (2°C to 8°C), protected from moisture and light, with the desiccant canister in place.
- After dispensing, tablets may be stored at room temperature (20°C to 25°C) for up to 3 months, protected from moisture.
- The prepared oral suspension can be refrigerated for up to 24 hours; discard any unused portion after that time.
Patient take-away
Key counselling points for a quick closing summary
- Amifampridine (RUZURGI) treats the muscle weakness of Lambert-Eaton myasthenic syndrome in patients 6 years and older.
- Treatment is started at a low dose and gradually increased based on response and side effects.
- Seizures and heart rhythm changes are serious risks; report any seizure, fainting, or irregular heartbeat right away.
- Never combine amifampridine with other forms of amifampridine or other aminopyridine drugs.
- Do not stop amifampridine abruptly, since this can cause a return of LEMS symptoms.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.